NCT06538038 2026-03-16
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
Recruiting
PrECOG, LLC.
Fundación GECP
Instituto Nacional de Cancerologia de Mexico
IRCCS San Raffaele
Peking University Cancer Hospital & Institute
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Swami Rama Himalayan University
Vall d'Hebron Institute of Oncology